Press Release
From Clinic to Home: Global Autoinjectors Market Accelerates on Biologics, Biosimilars and Self-Injection
FOR IMMEDIATE RELEASE | Global Data Route Analytics | September 2026
Home and self-care settings account for about 68% of Global Autoinjectors Market revenue in 2025 and reach USD 33,752.72 Million by 2035 at a 13.89% CAGR, as monoclonal antibodies, biosimilars and IV-to-subcutaneous conversion move chronic therapy out of the clinic.
The centre of gravity in injectable therapy has moved from the infusion chair to the kitchen table. Global Autoinjectors Market Size, Share, Trends & Forecast 2020–2035, published by Global Data Route Analytics, finds that home and self-care is the dominant end-use setting in the Global Autoinjectors Market, representing about 68% of revenue in 2025 and growing to USD 33,752.72 Million by 2035 at a 13.89% CAGR. Healthcare facilities, including hospitals, clinics, ambulatory and long-term care, reach USD 8,736.03 Million over the same period. The total market grows from USD 13,451.97 Million to USD 48,029.60 Million at 13.57%.
Patient self-administration is the leading administrator type, with caregiver, family-member and healthcare-professional administration quantified separately. The shift is driven by an ageing population, with the WHO expecting the number of people aged 60 and over to double to 2.1 billion by 2050, and by payer economics that favour hospital-at-home programmes over facility-based infusion.
|
Get the sample report with segment-level data tables and the full table of contents:
|
Biologics Are the Engine
Monoclonal antibodies and fusion proteins account for roughly 61% of 2025 revenue by drug modality. The report quantifies ten antibody classes delivered by autoinjector, including TNF-targeting, interleukin- and interleukin-receptor-targeting, IgE-targeting, CGRP-targeting, PCSK9-targeting and integrin-targeting antibodies, across therapy areas from rheumatology (USD 7,546.80 Million by 2035) and allergy, dermatology and immunologic disorders (USD 12,404.23 Million by 2035) to neurology, gastroenterology and respiratory disease.
Oncology is the next frontier. The first subcutaneous PD-1 inhibitors and the approval of KEYTRUDA QLEX pull cancer immunotherapy onto injector-compatible formats, while on-body and 5 mL+ platforms such as Enable Injections' enFuse and SHL Medical's Maggie 5.0 address the large-volume, high-viscosity presentations that IV-to-subcutaneous conversion requires. Container capacities over 2.25 mL are the fastest-growing capacity segment at a 14.67% CAGR.
Biosimilars Multiply the Device Base
- Ninety biosimilars are now approved in the United States, with interchangeability increasingly granted at the level of the individual autoinjector presentation.
- Celltrion, Samsung Bioepis, Fresenius Kabi, Viatris, Lupin, Sun Pharmaceutical, Zydus Lifesciences, Aurobindo Pharma, Baxter and Amneal are profiled in a dedicated biosimilar and specialty-injectable chapter.
- The report's price-analysis chapter models biosimilar price erosion and device-presentation pricing against each modality's revenue line.
- Randomised crossover trials cited in the report consistently show patients preferring autoinjectors to prefilled syringes, supporting adherence in unsupervised settings.
|
Need country-level, segment-level or company-specific data? Our analysts respond within one business day:
|
Human-Factors Risk in the Home
Self-injection places usability at the centre of safety. The report analyses FDA human-factors engineering guidance and ISO 11608 requirements, high-profile recalls where devices failed to activate or required excess activation force, and the needle anxiety that suppresses uptake in otherwise eligible patients. Use-error mitigation, training and connected adherence support are treated as competitive differentiators rather than compliance costs.
Recent Developments
Developments tracked include FDA approval of AstraZeneca's Saphnelo Pen for once-weekly self-administration in systemic lupus erythematosus, UCB's Bimzelx autoinjector presentations, Haselmeier's PiccoJect two-step autoinjector entering clinical trials, and embecta's acquisition of Owen Mumford with up to £50 million tied to Aidaptus autoinjector sales.
|
Buy the full report at a special introductory price:
|
About the Report
The 1,750-page study quantifies the Global Autoinjectors Market across twelve segmentation axes, five regions and 31 countries, includes a dedicated ten-dimension price-analysis chapter and profiles 151 companies across 15 chapters covering device manufacturers, platform and injection-technology companies, pharma users, biosimilar and specialty-injectable companies, connected-device, CDMO, primary-container, safety-syringe, automation and regional emerging-market companies. Deliverables include a 700+ table PDF and an Excel data pack with verified company and product links.
About Global Data Route Analytics
Global Data Route Analytics is a market research and consulting firm delivering syndicated and custom research across healthcare, life sciences, medical devices and adjacent industries. Our reports combine primary interviews, verified secondary sources and proprietary estimation models to give manufacturers, investors and policy teams a quantified basis for decisions.
Report: Global Autoinjectors Market Size, Share, Trends & Forecast 2020–2035
Media & Sales Contact: Global Data Route Analytics | globaldatarouteanalytics.com/contact